SCHEMBL23218128

SCHEMBL23218128

CCOC(=O)Cc1cccc(C(=O)OCC)c1OCc1coc2ccc(Br)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.40
LMNA P02545 2/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALOX5 P09917 2/20 0.38
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRB2 P47870 1/20 0.38
MAOA P21397 2/20 0.38
GAA P10253 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
TP53 P04637 1/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852861 1.00 MAOB (0.40) MAOBLMNAALDH1A1SMN1; SMN2ALOX5
SCHEMBL23218939 0.92 NPC1 (0.36) MAOBALDH1A1ALOX5MAOAGAA
SCHEMBL29852597 0.92 NPC1 (0.36) MAOBALDH1A1ALOX5MAOAGAA
SCHEMBL29853258 0.89 THRB (0.41) MAOBLMNAALDH1A1ALOX5MAOA
SCHEMBL23218680 0.89 THRB (0.41) MAOBLMNAALDH1A1ALOX5MAOA
SCHEMBL23218492 0.88 MEN1 (0.37) MAOBALDH1A1SMN1; SMN2ALOX5MAOA
SCHEMBL29853198 0.88 ALOX5 (0.38) MAOBALDH1A1ALOX5MAOAGAA
SCHEMBL23218199 0.88 ALOX5 (0.38) MAOBALDH1A1ALOX5MAOAGAA
SCHEMBL29593139 0.88 MEN1 (0.37) MAOBALDH1A1SMN1; SMN2ALOX5MAOA
SCHEMBL23218697 0.87 MAPT (0.40) MAOBLMNAALDH1A1SMN1; SMN2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MAOB 1035/4885LMNA 1698/4885ALDH1A1 2667/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MAOB 453/4885LMNA 1844/4885ALDH1A1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.